ArticleEndocrine2025
Diagnostic performance of ACR-TIRADS for thyroid nodule risk stratification in pediatric patients.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS) is a widely used ultrasonographic risk-stratification system for thyroid nodules in adults and its use has been increasingly expanding in the pediatric population in recent years. Here, we evaluated the diagnostic performance of ACR-TIRADS in patients aged ≤ 18 years with thyroid nodules.
methodsWe performed a single-center retrospective cohort study of patients aged ≤ 18 years, followed by tertiary care for thyroid nodules. The ACR-TIRADS data were extracted from the image records by two radiologists with expertise in thyroid imaging. Malignancy rates were defined based on cytological examinations, histological diagnosis, or ultrasonographic follow-up concerning nodule characteristics and size.
resultsThe cohort comprised 58 patients (65 nodules). The majority were female (70.7%), with a mean age of 14.0 ± 3.4 years and 27.5% had at least one risk factor for thyroid malignancy. The malignancy rate was 20.7% (N = 12). We could not reassess the ultrasound images of 9 patients; therefore, for this analysis, 49 patients (56 nodules) were included. The TIRADS nodule classifications were as follows: 8 TR1 (14.3%), 18 TR2 (32.1%), 15 TR3 (26.8%), 7 TR4 (12.5%), and 8 TR5 (14.3%). The ACR-TIRADS interobserver agreement was high, with a free marginal kappa of 0.86 [95% confidence interval (CI): 0.75, 0.97]. All TR1, TR2, and TR3 nodules were benign, and 8 cases of thyroid malignant neoplasm in the TR4 (N = 1) and TR5 (N = 7) groups resulted in malignancy rates of 14.3 and 87.5%, respectively. Remarkably, the TR5 nodules exhibited a positive predictive value of 87.5%, negative predictive value of 97.9%, sensitivity of 87.5%, and specificity of 97.9% for predicting malignancy. We did not identify a cutoff of nodule size for predicting malignancy - area under the receiver operating characteristic curve (AUC) of 0.58 (95% CI 0.38-0.80).
conclusionACR-TIRADS effectively stratifies malignancy risk in pediatric thyroid nodules, with TR5 nodules showing particularly high malignancy risk. Clinical risk factors combined with ultrasound characteristics provide better malignancy prediction than nodule size alone in this population.
Indexed as
Identifiers
40794379What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.